| The HHS Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission in the United States is accepting nominations |
Nominations for New Members for the HHS Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission in the U.S | The HHS Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission in the United States (the Perinatal Guidelines Panel) is accepting nominations for new scientific/clinical members with expertise in the care and treatment of pregnant people with HIV and the prevention of perinatal HIV transmission. The Panel is seeking candidates with expertise in obstetrics and gynecology, pharmacology, pediatrics, and infectious diseases. Panel members critically evaluate new information and prepare guidelines revisions. The candidates shall be recognized experts in their areas of interest with a record of publications and presentations. The successful candidates shall serve a three-year term beginning February 2022, with potential for reappointment. Because these are guidelines focused on management of HIV in people who are pregnant or are trying to conceive and the prevention of perinatal HIV transmission within the United States, candidates should be from the United States. The Perinatal Guidelines Panel is a Working Group of the Office of AIDS Research Advisory Council (OARAC) of the National Institutes of Health (NIH). The Panel is comprised of approximately 30 members who are clinicians, researchers, academicians, and HHS representatives with diverse expertise in the treatment of HIV during pregnancy and interventions for the prevention of perinatal HIV transmission (e.g., individuals with training in obstetrics/gynecology, infectious diseases, pediatrics, pharmacology) as well as community representatives with knowledge of HIV infection in pregnancy and interventions for preventing perinatal HIV transmission. The Panel meets monthly via teleconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy in pregnant women and interventions for perinatal transmission to update of the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States, which is found at https://clinicalinfo.hiv.gov/en/guidelines. Panel members are not compensated for their time commitment. The nomination should include a curriculum vitae and a letter of nomination or letter of interest with specific reference to how the nominee would contribute to the work of the Panel. Please submit nominations to Segun Adeyemi, Guidelines Coordinator, at segun.adeyemi@nih.gov. We are requesting that nominations be submitted by January 3, 2022. |
|
|
Community Member Nominations are Now Being Accepted for the HHS Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission in the U.S. The HHS Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission in the United States (the Perinatal Guidelines Panel) is accepting nominations for a community representative to serve a 3-year term beginning February 2022 with potential for reappointment for one additional term. Individuals who served as Panel members in the past are welcome to reapply. The Panel welcomes diversified representation in the community membership reflecting the demographics of the current HIV epidemic in the United States. Community members may assist the Panel in identifying and addressing unique treatment aspects that relate to the constituencies they represent. The candidate shall have knowledge and involvement in issues related to management of management of HIV in people who are pregnant or are trying to conceive, as evidenced by experience in HIV treatment, education, and/or advocacy programs or experience in clinical/public policy initiatives related to HIV treatment. The Perinatal Guidelines Panel is a Working Group of the Office of AIDS Research Advisory Council (OARAC) of the National Institutes of Health (NIH). The Panel is comprised of over 30 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy and revise the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Panel members are not compensated for their time commitment. The nomination should include a curriculum vitae and a letter of interest or a letter of nomination with specific reference to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Segun Adeyemi, Guidelines Coordinator, at segun.adeyemi@nih.gov no later than January 3, 2022. |
|
|
|
You are subscribed as newsletter@newslettercollector.com. Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit the GovDelivery Subscriber Help Center at https://insights.govdelivery.com/Communications/Subscriber_Help_Center.
This service is provided in collaboration with NIHs Office of AIDS Research and HHS Office of Infectious Disease and HIV/AIDS Policy/HIV.gov.
| This email was sent to newsletter@newslettercollector.com using GovDelivery Communications Cloud on behalf of: HIVinfo 8600 Rockville Pike Bethesda, MD 20894 888-346-3656 | |
